Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
In a report released yesterday, Tessa Romero from J.P. Morgan maintained a Buy rating on Cytokinetics. The company’s shares closed last Friday at $62.34.
According to TipRanks.com, Romero is a 5-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $91.71, representing a 49.6% upside. In a report issued on January 27, Barclays also initiated coverage with a Buy rating on the stock with a $87.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Boston Scientific (BSX)
In a report released yesterday, Joanne Wuensch from Citi reiterated a Buy rating on Boston Scientific, with a price target of $102.00. The company’s shares closed last Friday at $76.27.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $108.14, representing a 40.0% upside. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
